Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie
- Apr 20, 2022
- 2 min read
Updated: Sep 2, 2022
Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific NK cell Engager Therapy (TriNKET™) platform
WALTHAM, Mass., April 20, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced an expansion of its research collaboration with AbbVie (NYSE: ABBV) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases. AbbVie successfully licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019, in January 2021.
"AbbVie is committed to delivering transformative treatment options for patients suffering from autoimmune and fibrotic diseases," said Dr. Jonathon Sedgwick, Vice President and Global Head of Discovery Research at AbbVie. "We have seen strong progress in our current collaboration with Dragonfly focused on their triNKET technology and are pleased to expand our partnership to include additional immunology targets of interest to AbbVie."
"AbbVie is a global leader in treating immune-mediated diseases, and they continue to be a terrific partner" said Bill Haney, co-founder and chief executive officer of Dragonfly, "we look forward to building on our successful collaboration, and rapidly progressing with the AbbVie team to advance new treatment options for patients."
Under the agreement, Dragonfly will grant AbbVie the option to license exclusive worldwide intellectual property rights to multiple new candidates developed using Dragonfly's TriNKET™ technology platform. AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties.
About Dragonfly
Dragonfly Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough treatments to patients.
For more information visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne Deconinck | anne@dragonflytx.com
Related Links http://www.dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
Thanks for sharing this update. Medical and research developments like this are important to keep up with, and your car accident lawyer kitchener explanation was clear and helpful. I recently saw related coverage on a mirianlaw-based review blog and appreciated that perspective too.
I read this post about the collaboration between Dragonfly and AbbVie and found it quite insightful because it highlights how strategic partnerships in the biotechnology sector are essential for accelerating the discovery and development of innovative therapies. The article emphasises the expansion of their joint research efforts, particularly in using advanced immunotherapy platforms to address complex diseases such as cancer, autoimmune conditions, and fibrosis. It also demonstrates how collaboration between specialised biotech companies and large pharmaceutical organisations can combine scientific innovation with the resources needed to bring treatments closer to clinical application. This can be related to the Betaris Box Model, as shared goals, positive professional attitudes, and effective communication between organisations can influence behaviour, strengthen collaboration, and lead to…
Thank you for sharing this update. Medical research topics can feel overwhelming, and this was presented clearly and https://qualityfenceandcustomoutdoors.com/ thoughtfully. I recently read something related on a based review blog too.
This is such an exciting development in immunotherapy research! The expansion of Dragonfly's TriNKET™ platform through this deepened collaboration with AbbVie really highlights how strategic partnerships can accelerate breakthroughs in autoimmune and fibrotic diseases. What's particularly impressive is how quickly AbbVie moved to license the first TriNKET™ drug candidate — that kind of confidence speaks volumes about the platform's potential. As someone studying biomedical data analytics, reading about collaborations like this reminds me how critical rigorous statistical analysis is in validating these drug candidates. The data behind every milestone payment and trial outcome has to be airtight. In fact, many of my peers who struggle with the analytical side often look to Pay Someone to Write My SPSS Assignment when…
It's wonderful to read the post about Dragonfly Therapeutics' collaboration with AbbVie. I found the focus on advancing NK-cell-based immuno-oncology therapies using Dragonfly’s TriNKET platform quite interesting. The way they emphasize partnership to accelerate cancer research stood out. I also feel the article shows how biotech collaborations like this can shape future therapies, and while reading, I was reminded of how students often look for support services such as New Assignment Help Australia in academic work contexts. It is similar to searching for reliable guidance, like Best Assignment Help Australia, when managing complex topics naturally. Nice post